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Background: Insomnia is a significant risk factor for depression onset, can result in more disabling depressive
illness, and is a common residual symptom following treatment cessation that can increase the risk of relapse.
Internet-based cognitive behavioural therapy for insomnia has demonstrated efficacy and acceptability to men who
are less likely than women to seek help in standard care. We aim to evaluate whether internet delivered cognitive
behavioural therapy for insomnia as an adjunct to a standard depression therapeutic plan can lead to improved
mood outcomes.
Methods/Design: Male participants aged 50 years or more, meeting Diagnostic and Statistical Manual of Mental
Disorders criteria for current Major Depressive Episode and/or Dysthymia and self-reported insomnia symptoms,
will be screened to participate in a single-centre double-blind randomised controlled trial with two parallel groups
involving adjunctive internet-delivered cognitive behavioural therapy for insomnia and an internet-based control
program. The trial will consist of a nine-week insomnia intervention period with a six-month follow-up period. During
the insomnia intervention period participants will have their depression management coordinated by a psychiatrist
using standard guideline-based depression treatments. The study will be conducted in urban New South Wales,
Australia, where 80 participants from primary and secondary care and direct from the local community will be
recruited. The primary outcome is change in the severity of depressive symptoms from baseline to week 12.
Discussion: This study will provide evidence on whether a widely accessible, evidence-based, internet-delivered
cognitive behavioural therapy for insomnia intervention can lead to greater improvements than standard treatment for
depression alone, in a group who traditionally do not readily access psychotherapy. The study is designed to establish
effect size, feasibility and processes associated with implementing e-health solutions alongside standard clinical care, to
warrant undertaking a larger more definitive clinical trial.
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Symptoms of insomnia are commonly comorbid with
depression, particularly in older adults [1]. In this popu-
lation, although advanced sleep phase can occur, insom-
nia is the most commonly reported sleep disturbance;
this includes complaints of difficulty falling asleep, fre-
quent nocturnal awakenings, and early morning wakeful-
ness [2,3]. These lead to shorter overall sleep duration,
which in turn contributes to chronic patterns of mental
ill health [4]. Epidemiological studies suggest that in-
somnia is a significant risk factor for depression onset
and recurrence in both younger and older samples [5-7].
Insomnia comorbid with depression is indicative of a
more severe illness and, despite its implications, tends
to be under-treated [5]. In late life depression, sleep
disturbance appears to be most prominent at the onset
of the episode [8] and has been shown to be a prognostic
marker [9,10]. Insomnia may be separate or reflect an
inadequately treated episode of Major Depressive Disorder
(MDD). Reports of the prevalence of residual insomnia
symptoms in those responding to treatment for MDD,
range from 30% up to 90% [11]. Importantly, failure to
achieve full remission from even the first episode of MDD
is a strong predictor of recurrence and chronicity as
shown in landmark National Institute of Mental Health
studies [12] and confirmed in the STAR-D trial [13]. Fur-
ther, insomnia is the most common residual symptom
after completion of drug or therapeutic treatment of mood
disorder [11,12] occurring in up to two thirds of this
group in the STAR-D study [13]. Thus insomnia in elderly
people with previous MDD is a strong and independent
predictor of recurrent [10] and persisting MDD [9].
The question of whether adjunctive treatment of
insomnia can improve the standard treatment of de-
pression was addressed in a pilot trial by Manber et al.
[14]. They reported that the addition of seven sessions
of cognitive behavioural therapy for insomnia (CBTi) to
escitalopram resulted in a higher rate of remission of
depression (61.5%) than in the control arm (33.3%). The
adjunctive therapy was also associated with a greater re-
mission from insomnia (50.0%) as compared to control
(7.7%) and larger improvement in all diary and actigraphy
measures of sleep, except for total sleep time. More
recently, Watanabe et al. [15] demonstrated that four
weekly face-to-face sessions of CBTi as a supplement to
outpatient treatment in psychiatric clinics was associated
with higher rates of remission of depression (50.0%) com-
pared with treatment as usual (6.0%), with similarly
favourable rates of remission for insomnia (50.0% versus
0.0%). This study has since been extended by Wagley et al.
[16] using a briefer version of face-to-face CBTi in a
broader sample of patients with psychiatric disorders,
which has also shown significant reductions in both de-
pressive symptoms and sleep quality following treatment.Men with symptoms of depression and anxiety, par-
ticularly in the oldest and youngest age groups seek help
far less frequently than women for a given threshold
or condition [17]. Whilst help-seeking for depression
remains low, over half of people with insomnia seek
treatment in primary care [18] making it likely that an
insomnia intervention program would be well received
and utilised. Internet-based programs have some distinct
advantages in the delivery of treatment and prevention ser-
vices. Treatment using e-health applications is 20 times
more cost effective than face-to-face psychological treat-
ment and 50 times more efficient than medication in terms
of disability-adjusted life years averted [19]. However, we
are not aware of any study evaluating the use of adjunctive
internet-based CBTi in older men with depression.
With the development and initial evaluation of Sleep
Healthy Using the Internet (SHUTi), members of our
team have demonstrated the efficacy of an internet inter-
vention for adults with insomnia [20]. This intervention
is firmly grounded in the research supporting the effi-
cacy of face-to-face CBTi [21], including the primary
components of sleep restriction, stimulus control, cogni-
tive restructuring, sleep hygiene, and relapse prevention.
SHUTi is an interactive, self-help program, which is fully
automated and based on principles of self-help. In this
community-based study of adults with insomnia [20],
participants randomly assigned to receive SHUTi not
only experienced significant sleep improvements, but
also demonstrated improvements in comorbid psycho-
logical symptoms and quality of life, compared to those
in a wait-list control group [22].
As such, we hypothesise that providing SHUTi as an
adjunct to standard care in older men with comorbid de-
pression and insomnia symptoms will improve depression
more than an adjunctive controlled website providing
insomnia education alone.
Objectives
In older men with major depression, this trial aims to:
1. Investigate the efficacy of SHUTi as an adjunctive
treatment to standard beyondblue guideline-based
treatment [23,24] for reducing depression symptom
severity;
2. Determine whether adjunctive SHUTi decreases
anxiety and insomnia symptom severity;
3. Ascertain whether SHUTi is associated with changes
in actigraphy/sleep diary determined sleep in people
with comorbid depression and insomnia symptoms;
4. Explore the processes, predictors and mediators of
treatment response and of adherence to SHUTi by
determining user characteristics and behaviours that
may predict positive outcomes, adherence, trial
drop-out, and program acceptability.
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Trial design
The study is a single-centre double-blind randomised
controlled trial (RCT) with two parallel groups involving
an internet-delivered CBTi intervention and an insomnia
education control condition. The trial consists of a nine-
week insomnia intervention period and six-month follow-
up period. The intervention will be delivered as an adjunct
to standard guideline-based treatment for depression. As
such, during the intervention period, participants in both
arms will have their depression assessed, and the treat-
ment managed, by a psychiatrist in accordance withAllocated to Online Intervention 
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Figure 1 Proposed flow of participants.clinical practice guidelines [23,24]. At trial entry, and
after randomisation, participants will complete baseline
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They will then commence their internet-delivered CBTi
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as clinically required, to manage their depression. Six
months after completion of the post-intervention assess-
ment, participants will complete the self-report, psycho-
logical and sleep measures. As such there will be three
principal occasions of measurement over the full study
period: baseline, post-intervention, and 6-months post-
intervention, and the primary endpoint will be a reduction
in depressive symptoms at post-intervention (week 12).
The total trial period will be nine months. The trial has
been registered on the Australian and New Zealand
Clinical Trial Registry (ACTRN12612000985886). The trial
design is shown graphically in Figure 1.
Study setting
The target population for the SOMNA trial is Australian
male adults, aged 50 years and over, who meet diagnos-
tic criteria for a current depressive disorder and self-
reported sleep disturbance. Participants will be recruited
from local primary and secondary care providers, as well
as directly from the local community via newspaper and
radio advertisements, community organisation newsletters
and events. An online recruitment and marketing cam-
paign will also be implemented through help-seeking
websites and social media.
Eligibility criteria
Participants eligible for the SOMNA trial must comply
with all of the following at the point of randomisation:
1. Have a depressive disorder, defined as screening
positive (score greater than or equal to 8) on the
Quick Inventory of Depression Symptomology Self
Report (QIDS-SR) [25] at preliminary screening, and
meeting Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) criteria for current Major
Depressive Episode and/or Dysthymia at clinical
interview using the Structured Clinical Interview for
DSM-IV (SCID) [26];
2. Report insomnia symptoms above threshold
(score greater than or equal to 8) on the Insomnia
Severity Index (ISI) [27] at preliminary
screening; and,
3. Have provided written informed consent before any
trial procedures are undertaken.
Participants will be excluded from participating in the
SOMNA trial if at the point of randomisation they:
1. Have a prior history of psychosis or hypo/manic
episodes, determined either during phone screening
or at clinical interview;
2. Have current substance dependence, determined at
clinical interview;3. Score less than 24 on the Mini Mental State
Examination (MMSE) [28], determined at clinical
interview;
4. Are a rotating shift worker with overnight shifts;
5. Have undertaken transmeridian travel in the past
month, where the time difference is greater than
two hours and there has been an inadequate period
to readjust to local time (adjustment defined
as requiring 48 hours for every one hour time
difference);
6. Meet criteria for Restless Legs Syndrome (RLS) as
defined using the Cambridge-Hopkins RLS short
form diagnostic questionnaire [29];
7. Are at high risk for obstructive sleep apnea (OSA) as
defined by the Berlin Questionnaire [30], or have
been treated for sleep apnea.
Interventions
All eligible participants will be randomised on a 1:1 basis
to receive either SHUTi or the web-based insomnia edu-
cation control program.
Active treatment arm: SHUTi
The Sleep Healthy Using the Internet (SHUTi, http://
shuti.me) program is firmly grounded in research sup-
porting the efficacy of face-to-face Cognitive Behavioural
Therapy (CBT) for insomnia [20]. Described in detail
elsewhere [31], SHUTi consists of six core modules
addressing behavioural, educational and cognitive tech-
niques, incorporating sleep restriction and stimulus
control, sleep hygiene, cognitive restructuring and re-
lapse prevention. Content is presented in an interactive
format featuring text, graphics, audio and animations.
The program utilises vignettes and quizzes to deliver in-
formation, and provides individually tailored recom-
mendations to help improve sleep as informed from
sleep diary information submitted by users. The six core
modules are available to complete sequentially and
completion involves up to an hour per week, over a
nine-week period. Participants are also encouraged to
submit daily sleep diaries each week. An automated
email notifies participants that a new module is avail-
able for completion. At the beginning of each new module,
participants receive recommendations for sleep restric-
tion treatment based on their completion of the previ-
ous weeks online daily sleep diaries, along with a review
of relevant information from previously completed
modules. Participants are able to move forward to the
next module one week after the previous module is
completed in full. Automated midweek reminders to
enter sleep diaries, implement strategies and commence
the next module are also sent. Each module remains
available once it has been completed so participants
may review all program content.
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The insomnia education control program provides cred-
ible sleep health information addressing the impact and
prevalence of insomnia, along with common causes and
symptoms of insomnia. It provides limited sleep hygiene
information pertaining to lifestyle and environmental
factors that may affect sleep. While behavioural and
cognitive techniques are mentioned in the control pro-
gram, unlike SHUTi, the strategies are not obtainable in
a tailored, metered, or interactive fashion, but rather
the content is presented in a basic text format only.
Consideration of the content requires approximately
30 minutes. However, the insomnia education program
(but not sleep diaries) is available for further review by
participants at any time over the nine-week intervention
period.
Clinical treatment for depression
As part of standard treatment for depression, all partic-
ipants will undergo a clinical assessment with a psych-
iatrist prior to study commencement, whereupon a
depression treatment plan will be prepared in accord-
ance with clinical practice guidelines [23,24]. This will
include watchful waiting, referral to psychotherapy or
other interventions such as couple therapy, or medi-
cation use under standard collaborative care with the
patient’s GP. The assessment will include the Mood
Episode and Disorder modules, and the Substance
Abuse screens of the SCID, standard clinician rated
measures: the 17-item Hamilton Rating Scale for De-
pression (HAM-D) [32], and the Hamilton Rating Scale
for Anxiety (HAM-A) [33], Mini Mental State Examin-
ation [28], Global Assessment of Functioning (GAF)
[34], Social and Occupational Functioning Assessment
Scale (SOFAS) [35] and Cumulative Illness Rating Scale
for Geriatrics (CIRS-G) [36] as well as completion of a
full psychiatric and medical history. After two weeks,
participants will be required to undergo a clinical review
with the psychiatrist, in accordance with their treatment
plan. Over the subsequent nine weeks, participants will
undergo further psychiatric review and management as
clinically required. Standard clinical instruments will be
administered to monitor depressive symptoms over this
period. If any changes to medication dosage are required,
this will be discussed between the patient, trial psychiatrist
and/or referring doctor. At the end of the trial period the
participant will be referred back to their GP or treating
doctor, or if required, managed in the trial clinic until
appropriate for discharge.
Participant monitoring and program adherence
While individual completion of SHUTi and the insomnia
education control programs will be systematically tracked
using methods embedded in the website infrastructure,their completion (or otherwise) will be achieved without
any direct supervision or encouragement from the trial
team. Participants will be able to seek technical support
as needed (e.g. if a username or password is forgotten)
but as this is a trial of an adjunctive insomnia treatment,
no specific clinical support will be provided. Further-
more, as all participants will be under the clinical care
of their treating psychiatrist, safety and general moni-
toring will be conducted at each scheduled clinical re-
view and follow-up appointment(s). Research assistants
will contact all participants by telephone at Week 4 and
Week 8 (as indicated in Figure 1) whereby data will be
collected against the primary and secondary outcome
measures, addressing mood state and insomnia symp-
toms. Participants demonstrating deterioration in mood
state will be referred to their treating psychiatrist for
risk management and follow-up.
Self report measures
Primary outcome
The primary outcome is change in severity of self-
reported depressive symptoms from baseline to three
months, as measured by the Centre for Epidemiological
Studies Depression scale (CES-D) [37]. The 20 items in
the CES-D measure symptoms of depression over the
past week on a 0–3 scale, and provide a summary score
ranging from 0 to 60 with higher scores indicating the
presence of greater depressive severity. Although origin-
ally created for the general population, the CES-D is a
reliable and valid measure of depressive symptoms and
widely used in clinical populations [38]. A self-report
measure, the CES-D will be embedded into each of the
formal assessments at baseline, post-intervention and
six-month post-intervention follow-up. The change in
severity of clinician-rated depressive symptoms over a
three-month period, will also be determined using the
HAM-D [32]. Considered the gold standard depression
assessment tool, the HAM-D is the most widely used
clinician-administered scale in clinical trials of anti-
depressant treatment. It rates the severity of symptoms
observed in depression such as low mood, insomnia,
agitation, anxiety and weight loss, with higher scores
indicative of more pronounced symptomatology. Mean
changes in continuous depressive symptom scores from
baseline will be compared between the two randomised
groups at three-months. Change scores will be based on
summed scores derived from the CES-D and the HAM-D
respectively.
Secondary outcomes
Secondary outcomes will comprise changes in the severity
of self-reported anxiety and insomnia symptoms respect-
ively. Anxiety symptoms will be assessed measured by the
State Trait Personality Inventory (STPI – Trait only) [39].
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to measure dispositional anxiety, anger, depression and
curiosity in adults i.e. how they “generally feel”. It con-
sists of four 10-item subscales with each item rated on a
four-point frequency scale. Higher scores are positively
correlated with higher levels of dispositional emotional
states. The STPI is a widely used measure and has high
validity and reliability, particularly for the anxiety and
anger scales [39]. Mean changes in total summed scores
from baseline to three-month follow-up will be com-
pared between the two randomised groups.
Insomnia symptoms will be measured by the Insomnia
Severity Index (ISI) [27], which assesses insomnia symp-
tom severity, distress and daytime impairment over the
past two weeks. Each of the seven items are assessed on
a likert-based scale which provide an overall quantitative
score ranging from 0 to 28, with higher scores indicative
of more severe insomnia. The tool has been shown to be
a valid and reliable measure [27] and is sensitive to
change following intervention for primary insomnia in
older adults [40]. In the current investigation, mean
changes in continuous insomnia symptom scores from
baseline will be compared between the two randomised
groups at three-month follow-up.
Tertiary outcomes
Changes in actigraphic and sleep diary assessed sleep pa-
rameters (total sleep time, sleep efficiency, wake after sleep
onset, sleep onset latency), hypnotic use, sleep beliefs (Dys-
functional Beliefs about Sleep (DBAS); [41]), the clinician
rated scales above and self reported health related quality of
life (Medical Outcomes Study Short-Form Health Survey;
SF-12) will be measured at baseline and post-intervention.
In addition, user characteristics predictive of outcome such
as demographic, health and lifestyle factors will be de-
scribed by treatment group at trial entry and overall at
three and six months. Program adherence and drop-out
will be monitored throughout the intervention period, and
evaluation measures will be measured at post-intervention.
Participant timeline
Potential participants will visit the trial-specific website
www.somna.com.au where they will be provided with
detailed information about the trial, the procedures and
time commitment involved in participation, the random-
isation process, and confidentiality, and contact details
for the trial team should they want further information.
The Participant Information Statement and Consent
Form will be published on the website and available for
download. Those interested in participating in the trial
will undertake an online consent and preliminary eligi-
bility screening procedure.
Completion of online consent and preliminary eligibility
screening requires potential participants to provide theirfull name and contact details, along with their date of
birth, gender and confirmation of their regular access to
an internet-enabled computer or device and availability
to attend the Trial Coordinating Centre on at least four
occasions. Potential participants will then be asked gen-
eral information pertaining to current sleep habits, and
to complete the QIDS-SR, ISI and RLS screening tools.
Interested participants are asked to sign the consent
form by dragging their mouse to create their signature,
thus giving permission to the research team to assess
their preliminary screening responses and contact them
to conduct an interview over the telephone to further
confirm eligibility to participate. This process also creates
a unique profile (trial identification number) for the
potential participant within the trial website.
Upon submission of the online consent and prelimin-
ary screening questionnaire, a member of the SOMNA
trial team will assess the potential participant’s eligibility
against the trial inclusion criteria. Those that do not
meet criteria will receive an email outlining why they
have not been selected to participate and will be pro-
vided with a resource sheet outlining options for alterna-
tive treatment or support for depression and sleep
concerns. A research assistant will contact those who
meet trial inclusion criteria via telephone, and an inter-
view assessment against the trial exclusion criteria will
be completed. Participants who do not meet criteria,
due to prior diagnosis of psychosis or hypo/manic epi-
sodes, high risk or prior diagnosis of sleep apnea, or
who report they are a rotating shift worker, will be
thanked for their time and will not participate further. If
required further referral information will be provided. If
potential participants report recent transmeridian travel,
they will be invited to undergo all preliminary depres-
sion and insomnia screening questions again once they
have had opportunity to readjust to the present time
zone. Wherever psychiatric history is unclear, partici-
pants will be invited to attend for baseline assessment
whereby the trial psychiatrist will undertake a compre-
hensive clinical interview to confirm diagnosis.
Following telephone screening, all eligible participants
will be invited to attend the Trial Coordinating Centre
(Brain & Mind Research Institute, Sydney, Australia)
to commence baseline assessment. Whilst at the Trial
Coordinating Centre, the participant will complete the
baseline medical assessment and clinical interview and
an online self-report questionnaire. Ongoing participa-
tion in the trial will be measured from this time-point.
As part of the baseline assessment, participants will be
provided with an actigraphy watch to wear on their
wrist for the subsequent two weeks, and they will be
instructed to log into the SOMNA website each day
during this period to submit sleep diaries. Upon comple-
tion of ten diaries in a 14-night period the participant will
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Full informed, written, consent will be obtained prior to
any study procedure being undertaken.
Upon completion of the nine-week intervention period,
participants will be prompted by automated email to
return to the trial website to complete the post-
intervention self-report questionnaire. Personalised
emails, text message reminders and telephone calls will
be made to participants who do not respond to encour-
age completion. Participants will also be invited to
return to the Trial Coordinating Centre to complete the
post-intervention medical assessment, and have the
option of completing the online questionnaire at that
time too. As per the baseline assessment, they will be
provided with an actigraphy watch to wear on their
wrist for the subsequent two weeks, and they will be
instructed to log into the SOMNA website each day
during this period to submit sleep diaries.
A final follow-up assessment will be completed six-
months later, although on this occasion only self-report
measures will be collected through the study website.
Personalised emails, text message reminders and tele-
phone calls will be made to participants who do not
initially respond. Refer to Figure 1 for further detail re-
garding the timeframe for follow-up assessments.
Where participants are unable to complete follow-up
self-report assessments online, a hardcopy of the as-
sessment will be mailed to them for completion at
home. Alternatively, a blinded research assistant may
complete the assessment over the telephone. Where a
participant discontinues their assigned intervention,
all efforts will be made to retain the participant in the
trial to enable follow-up data collection and prevent
missing data.
Sample size
In older adults, literature suggests depression treatment
comprising pharmacotherapy or psychotherapy will elicit
medium effects on symptomology. In the secondary ana-
lysis of the primary SHUTi trial, the effect of the inter-
vention on depressive symptoms was larger than this,
with a reported effect size on reducing depressive symp-
toms of 0.72 pre and post assessment using the Beck
Depression Inventory [22]. Although noting this was
detected amongst a community sample with mild de-
pressive symptoms, we hypothesise that an adjunctive
SHUTi intervention will lead to a small to moderate ef-
fect size over and above the effect of standard guideline-
based depression treatment in a naturalistic setting. We
propose to conduct a randomised controlled trial that
will seek to establish the true effect size, along with
feasibility of conducting a definitive clinical trial in a
large-scale primary care setting that would provide evi-
dence on the potential benefit of an adjunctive insomniaintervention for depression amongst older men. We will
attempt to recruit a minimum of 80 participants with 40
per group (36 per group with 10% attrition) for the com-
parison of endpoint depression scores between the
SHUTi intervention and the control condition.
Recruitment
Trial participants will be recruited into the study on a
rolling basis over a period of 18-months. The entire
study is expected to be complete within three years.
Allocation
The allocation of participants to study arm will be
undertaken by a staff member who is independent of the
study operations and has no day-to-day contact with
participants. Once full informed consent is obtained and
the trial psychiatrist has assessed eligibility and made the
decision to enrol a participant, a research assistant will
notify the independent staff member to perform the ran-
dom allocation. Treatment allocation will be undertaken
in accordance with the electronic randomisation schedule,
which will be generated by the unblinded trial manager
prior to trial commencement, password-protected and
saved on a secure network. In addition to documenting
each allocation on the randomisation schedule, so as to
generate a unique username and password to enable each
randomised participant access to their allocated website
program, the independent staff member will be required
to assign the allocated program to the user’s profile in the
trial website.
Sequence generation
The allocation sequence will be generated using a
randomly generated number sequence calculated used Re-
search Randomizer (http://www.randomizer.org/) prior to
trial commencement. The fully replicable sequence will be
based on permuted blocks, and eligible participants will be
stratified according to presenting depression severity (their
summed HAM-D score obtained during the baseline
medical assessment and clinical review) to ensure par-
ticipants with higher levels of symptoms are distributed
equally across both conditions. In accordance with se-
verity classification that maximises the sensitivity and
specificity of the HAM-D scale, symptom severity will
be collapsed into two categories including mild-moder-
ate scores <17; moderate-severe scores ≥17 [42]. The
allocation sequences within each strata will be pre-
generated by the unblinded trial manager and docu-
mented in the randomisation schedule prior to trial
commencement.
Allocation concealment mechanism
The allocation codes will be saved in a password-
protected file accessible only to the independent staff
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blinded trial manager, not to be provided until the
completion of the trial, unless unblinding is required
in an emergency. The allocation code assigned to any
participant will only be broken by the Chief Investiga-
tor or trial manager if the patient’s safety is at risk and
it is absolutely necessary to ascertain the website pro-
gram they were allocated. Given the low risk of the
intervention under study, this scenario is unlikely to
eventuate. However, where patient safety is under con-
sideration, disabling access to the website program will
be the preferred management option in contrast to
unblinding.
Blinding (masking)
This is a double-blind clinical trial whereby the study
participants and the clinical investigators / trial monitor-
ing staff, including the treating psychiatrist, will be un-
aware of treatment assignment. Only the trial manager,
the Internet program system administrator and the trial
statistician will have access to unblinded data at the indi-
vidual level. However, they will not have any direct ac-
cess to trial participants.
Several strategies will be employed to minimise bias
through accidental unblinding. Knowledge of treatment
allocation will be minimised by virtue of the intervention
delivery method being web-based, along with all self-
report assessments. Personnel who are unaware of the
participant’s treatment allocation will assess all clinical
outcomes. On each occasion of clinical assessment, par-
ticipants will be reminded that staff must remain blinded
to treatment allocation, and as such they should refrain
from describing or discussing their website program. In
the event that treatment allocation is accidentally re-
vealed to a staff member during an assessment, an alter-
native assessor, who is blind to allocation, will conduct
subsequent follow-up assessments. The trial manager
will maintain an unblinding log to record any specific
personnel that may be accidentally (or deliberately) un-
blinded during the course of the trial, along with the
date, scope and reason for doing so.
Data collection methods
Reasons for exclusion, withdrawal, discontinuation of
the website program or the depression treatment plan,
or loss-to-follow-up will be recorded. Table 1 provides
an overview of the timeframe for all assessments and the
measures that are used. All self-report measures, includ-
ing sleep diary entries, will be collected via the study
website at baseline, three and six-month time-points.
All clinical (medical, psychiatric and actigraphy) data
will be collected using standardised instruments and
tools by staff trained in the trial protocol and procedures
at baseline and three-months. All medical and psychiatryassessments will be performed at the Trial Coordinating
Centre, whereas actigraphy data will be collected via the
watch worn by participants in their homes. Clinicians
will be given a hardcopy case record form (CRF) in
which they will document results, including actigraphy,
which will be downloaded when the watch is returned.
Clinicians will be required to sign-off on the CRF on
completion of each assessment.
Data management
All consenting participants will be allocated a unique
identifier at the time of preliminary screening and this
identifier will be used exclusively to link all data col-
lected as part of the trial. All self-report data will be
collected via the secure internet site that delivers both
arms of the treatment program (intervention and
control). This data will be held on a secure server
maintained by the provider of the internet-delivered
interventions, BeHealth Solutions, and will only be
transferred to the secure master trial database at the
Trial Coordinating Centre at trial-end.
All clinical data (medical, psychiatric and actigraphy)
will be entered electronically into the master trial data-
base by suitably qualified staff, supervised by the trial
manager. Data will be entered into a user-friendly
Filemaker platform and integrity will be enforced
through a variety of mechanisms, including referential
data rules, valid values, range checks and consistency
checks. The option to choose a value from a list of
valid codes will also be available when applicable. The
master trial database will be held on a secure server
hosted by the Faculty of Medicine, University of Syd-
ney. The trial database will be password protected, and
only authorised trial personnel will have access. The
database will be maintained in accordance with Uni-
versity of Sydney Information and Communication
Technology policy and procedures. Upon database
lock, data will be exported to a statistical software
package for subsequent analysis.
Statistical methods
Primary outcome analysis will be undertaken on an
intention-to-treat basis. Mixed-model repeated mea-
sures analyses will be used because of the ability of this
approach to include participants with missing data.
Characteristics of the participants including sociodemo-
graphics, physical activity, health and lifestyle factors
will also be described by treatment group and overall.
Safety criteria including adverse events and withdrawals
will also be analysed. The type one error will be set at
5%. Descriptive statistics will include number of partici-
pants (N), mean, standard deviation, minimum, max-
imum and if a non- normal distribution, the median
and first/third quartiles will be reported.
Table 1 Complete list of assessments and measures
Recruitment/
screening
Baseline
assessment
Visit 1 Monitoring
calls
Post-intervention
follow-up assessment
Post-intervention
follow-up assessment
6 Month post-intervention
follow-up assessment
Early
termination
Time-point (Week) - 4 1 3 4 and 8 12 14 36
Assessments
Informed consent X X
Inclusion/exclusion criteria X X
Self report measures X X X X
Sleep diary X X X
Actigraphy X X
Psychiatric assessment X X X
Medical check-up* X X X
Monitor for suicidality* X X X X
Adverse events* X X X
Forms/measures
Depression (QIDS) X
Restless legs (RLS) X
Insomnia (ISI) X X X X X
Obstructive sleep apnea (Berlin questionnaire) X
Psychiatric diagnosis (SCID) X X
Global functioning (GAF) X X
Depression (HAM-D) X X X
Anxiety (HAM-A) X X
Disease burden (CIRS-G) X
Social and occupational functioning (SOFAS) X X
Cognition (MMSE) X
Depression (CES-D) X X X X
Anxiety (STPI) X X X
Sleep (DBAS) X X X
Sleep (MEQ) X
Health and wellbeing (SF-12) X X X
Alcohol use (AUDIT) X X X
Physical activity X X X
Personality (Locus of control) X
Program evaluation X
*Additional clinical reviews will be scheduled on an individual basis in accordance with personalised depression treatment plan.
Key to Abbreviated Forms/Measures: QIDS (Quick Inventory of Depressive Symptomatology); RLS (Restless Legs Syndrome Rating Scale); ISI (Insomnia Severity Index); SCID (Structured Clinical Interview for DSM-IV Disorders);
GAF (Global Assessment of Functioning); HAM-D (Hamilton Rating Scale for Depression); HAM-A (Hamilton Anxiety Rating Scale); CIRS-G (Cumulative Illness Rating Scale for Geriatrics); MMSE (Mini Mental State Examination);
CES-D (Center for Epidemiologic Studies Depression Scale); STPI (State Trait Personality Inventory); DBAS (Dysfunctional Beliefs About Sleep Scale); MEQ (Morning-Eveningness Questionnaire); SF-12 (Short Form
12-Item Survey); AUDIT (Alcohol Use Disorders Identification Test).
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The accuracy, completeness and progress of data will be
monitored continuously throughout the trial. Each CRF
will have a data checklist attached, on which the assess-
ments completed and other information will be re-
corded. Any missing information or illegible data will be
queried with the researcher, clinician or interviewer re-
sponsible for its collection. Audits will be undertaken
periodically to ensure that all data relating to informed
consent, self-report questionnaires, medical and psychi-
atric assessment, and actigraphy, are accounted for, and
that psychiatric assessments are standardised. All ori-
ginal CRFs will be stored securely by trial identification
number at the Trial Coordinating Centre.
Following data entry into the master trial database,
data will be randomly checked for accuracy and com-
pleteness and verified against source data. Approxi-
mately 5% of participants will be specifically monitored.
Safety and event monitoring
The intervention under study is considered low-risk,
with the only safety concern associated with the active
SHUTi intervention related to increased tiredness and
its sequelae due to restricted time spent in bed (as per
the behavioural treatment for insomnia). This risk is
mitigated directly through the program, which does not
restrict sleep by fewer than five hours. In light of this,
and given that all trial participants will be under the
clinical care of their treating psychiatrist throughout the
intervention period, an independent Data and Safety
Monitoring Committee will not be established.
Harms
During the course of the study, participants will be
assessed for both expected and unexpected adverse
events (AEs) at each clinical and research assessment
time point. Adverse events will be defined as any un-
favourable and unintended sign, symptom or disease
temporarily associated with the use of the intervention
under investigation. Medical conditions or diseases
present before starting the intervention will be consid-
ered adverse events only if they worsen after starting the
trial and that worsening is considered to be related to
the study intervention. An AE will also be extended to
include any undesirable and unintended effect of re-
search occurring in trial participants as a result of the
collection of identifiable private information under the
research. An AE will be deemed serious if it is deter-
mined to be associated, or possibly associated with
study involvement, and results in either: death, is life-
threatening, requires or prolongs hospitalisation, or
results in persistent or significant disability or incap-
acity. Expected AEs will include: initial discomfort or
embarrassment due to personal or sensitive nature ofresearch questions; concerns related to internet-based
data collection and storage procedures; and initial tired-
ness, fatigue and possible concentration problems as a
result of sleep restriction techniques to improve sleep
habits.
Adverse events will be detected at the Week 3 clinical
review and Week 12 follow-up assessment. In addition,
research assistants conducting routine monitoring tele-
phone interviews at Weeks 4 and 8, will also have
capacity to detect AEs.
All AEs (including Serious Adverse Events, or SAEs),
regardless of relatedness to the interventions under in-
vestigation, will be recorded, classified and graded on an
adverse event form. Recording will be completed in a
concise manner using standard, acceptable medical
terms. All SAEs will be reported to the Human Research
Ethics Committee within 72 hours.
Study sponsorship and organisation
The sponsor of the trial is the University of Sydney.
SHUTi and the control program will be provided by
BeHealth Solutions. The trial is supported by beyond-
blue: the national depression and anxiety initiative Na-
tional Priority Driven Research Program and funded
through a donation from the Movember Foundation.
The trial will be coordinated independently of the spon-
sor, funder and supplier of the intervention programs, by
the Brain & Mind Research Institute, Sydney, Australia
and overseen by the Trial Management Committee com-
prising the Chief Investigator team.
Ethical considerations
The trial will be undertaken in compliance with the
World Medical Association Declaration of Helsinki (re-
vised version of Seoul, 2008), international standards of
Good Clinical Practice and the applicable regulatory re-
quirements in Australia. The design and implementation
of the trial has been approved by The University of Syd-
ney Human Research Ethics Committee (Reference
Number: 2012/2182). All important protocol modifica-
tions will be communicated to the Human Research Eth-
ics Committee prior to implementation.
Discussion
This RCT will provide evidence on whether a widely
accessible, evidence-based, internet-delivered CBTi inter-
vention can also improve other clinical outcomes in a
population receiving standard treatment for depression,
which traditionally do not readily access current care
systems. The outcomes may also be readily applicable
for translation into health care in other settings. Finally,
the study will provide the required information to in-
form the conduct of a definitive RCT.
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